Here, we describe the identification of a NAB2-STAT6 fusion from whole-exome sequencing of 17 SFTs. Analysis in 53 tumors confirmed the presence of 7 variants of this fusion transcript in 29 tumors (55%), representing a lower bound for fusion frequency at this locus and suggesting that the NAB2-STAT6 fusion is a distinct molecular feature of SFTs.
To better understand the molecular lesions contributing to SFT, we performed whole-exome sequencing of DNA isolated from SFTs and matched blood from 17 affected individuals ( Supplementary  Table 1 ). On average, we sequenced a median of 28.9 Mb per tumor, and 87.5% of the captured exons were covered to a depth of 20× or greater. An average of 22.5 nonsynonymous somatic mutations was observed per tumor across the 17 samples (median of 19; range of 12-41; median rate of 0.66 mutations per Mb; Supplementary Fig. 1 ). This corresponded to 390 somatically mutated genes, with 1 gene mutated in 2 samples (RBPJ) reaching nominal statistical significance for recurrence (q < 0.1; Supplementary Tables 2 and 3 and Supplementary Methods). Read count analysis of the tumor copynumber profiles showed 11 tumors with structurally undisrupted genomes and no obvious gains or losses, whereas 6 tumors showed a broad loss of chromosome 13, including 2 samples with a concurrent broad gain of chromosome 8 (Supplementary Fig. 2) .
Given that the formation of many soft-tissue tumors is driven by genomic translocations 1 , we explored the possibility that gene fusions might contribute to tumorigenesis in SFT. Using wholeexome sequencing data, our fusion detection was limited to breaks that occurred within exons or near intron-exon boundaries. However, we identified 19 potential fusion events in 10 of 17 tumor samples using algorithms designed for this application (Supplementary Table 4 and Supplementary Methods).
Rearrangements in 7 of 17 tumors represented in-frame fusions of the NAB2 and STAT6 genes, both located on chromosome 12 (Supplementary Fig. 3a ). Sequence review identified paired-end reads where one read mapped to an exonic region of NAB2 and its corresponding read mapped 1.8 to 5.2 kb before the transcriptional start site of STAT6 ( Supplementary Fig. 3b and Supplementary npg of a DNA fragment were mapped in opposite orientations on the same strand ( Supplementary Fig. 3b ), we concluded that this fusion was likely due to an intrachromosomal inversion that juxtaposed NAB2 and STAT6 (Fig. 1a) . Normally, NAB2 and STAT6 are in opposite orientations, but the predicted inversions bring the two genes in close proximity in the same orientation (Fig. 1a) . In all cases, we also identified at least one sequence that spanned the NAB2-STAT6 fusion boundary. We confirmed the genomic breakpoint in two tumors by sequencing PCR products generated with breakpoint-spanning primers ( Supplementary Fig. 4 and Supplementary Table 5 ). The fusion was not observed in DNA from matched normal tissue (data not shown).
To analyze the expression and frequency of NAB2-STAT6 fusions, we performed RT-PCR using primers placed within exons 2-3 of NAB2 and within exon 1 of STAT6 on cDNA generated from 53 tumor samples representing 48 affected individuals ( Supplementary  Tables 1 and 5 ). An RT-PCR product was identified in 27 tumors from 23 individuals (51%). Sequencing of these products revealed multiple isoforms of the fusion that varied in the location of the fusion breakpoint within NAB2 ( Fig. 1b and Supplementary Fig. 4) . The NAB2 sequence was followed by a sequence belonging to the 5′ UTR of STAT6. Comparison of the cDNA structure to the inversion structure identified at the genomic level indicated that the region between exon 5 of NAB2 and the beginning of STAT6 (~10 kb) is spliced during transcription or that a large portion of this intronic region is deleted when the chromosome is rearranged. Additionally, we identified rare NAB2-STAT6 fusions, where the fusion breakpoint occurred in downstream exons of STAT6 in 2 of 17 cases from whole-exome sequencing data ( Supplementary Table 4 ).
NAB2 encodes a transcriptional repressor of the zinc-finger transcription factors EGR1 and EGR2, effectors of transforming growth factor (TGF)-β signaling in smooth muscle 2, 3 . NAB2 contains two conserved domains that interact with EGR1 to mediate multimerization and repress transcription 2,3 . Functional alterations of NAB2 have not been identified in cancer, but loss is reported in prostate cancer, lung cancer, non-Hodgkin lymphoma and neuroblastoma, and overexpression has been found in melanoma, Ewing sarcoma and rhabdomyosarcoma [4] [5] [6] .
STAT6 is a transcription factor that modulates signaling by interleukin (IL)-4 and IL-13 in the immune system 7 . Activation of STAT family members in cancer underlies the hypothesis that these proteins are potential therapeutic targets 8 . STAT6 in particular has been associated with increased proliferation and invasiveness in glioblastoma 9 . On the basis of the properties of NAB2 and the oncogenic potential of STAT6, we hypothesize that the NAB2-STAT6 fusion protein homodimerizes through the oligomerization domain of NAB2, translocates to the nucleus and modulates STAT6-dependent gene expression. In experimental systems, fusion of STAT3 to a portion of the estrogen receptor results in a similar phenomenon 10 .
In summary, we have identified a new NAB2-STAT6 fusion in at least half of SFTs from whole-exome sequencing data. Although most fusions are identified from whole-genome or whole-transcriptome sequencing, this finding validates the use of exome data for the discovery of fusions that occur mid-exon. The NAB2-STAT6 fusion seems to be unique to SFT samples, as fusion analysis of approximately 713 unique tumor-normal pairs from 5 tumor types analyzed by whole-genome, whole-exome or whole-transcriptome sequencing or a combination of these techniques [11] [12] [13] [14] [15] did not identify any fusions involving these genes. As such, this fusion represents the first molecular feature unique to SFT. These data also suggest that small molecule inhibitors of STAT6 might be efficacious in this tumor type. Further experiments investigating the functional behavior of this fusion protein are ongoing. Our estimates of the frequency of NAB2-STAT6 fusions should be considered a lower bound because whole-exome sequencing would not identify intronic breaks and because our RT-PCR approach was limited to the regions covered. 
